Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition
Alina Goerg(University Hospital Regensburg), Gero Brockhoff(University of Regensburg)
Cited by 4
Related Papers
Humanized tumor mice—A new model to study and manipulate the immune response in advanced cancer therapy
|International Journal of Cancer|2011|105
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
|British Journal of Cancer|2012|59
Modular anti‐EGFR and anti‐Her2 targeting of SK‐BR‐3 and BT474 breast cancer cell lines in the presence of ErbB receptor‐specific growth factors
|Cytometry Part A|2011|35